Clinical Transplants 2013 Individual Chapter Downloads

2013 Annual Literature Review of Donor-specific HLA Antibodies After Organ Transplantation.

2013 Annual Literature Review of Donor-specific HLA Antibodies After Organ Transplantation. Kan..

$0.00

2013 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current Uses and Outcomes of Hematopoietic Cell Transplants for Blood and Bone Marrow Disorders.

2013 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current..

$0.00

A Common Blood Gene Assay Predates Clinical and Histological Rejection in Kidney and Heart Allografts.

A Common Blood Gene Assay Predates Clinical and Histological Rejection in Kidney and Heart Allograft..

$0.00

A Critical Analysis of Quantitating Flow Cytometry: The Role of the Crossmatch in 2014.

A Critical Analysis of Quantitating Flow Cytometry: The Role of the Crossmatch in 2014. Rosenbe..

$0.00

A Regulated System of Incentives for Living Kidney Donation: Why Can't We Agree to Do a Trial?

A Regulated System of Incentives for Living Kidney Donation: Why Can't We Agree to Do a Trial? ..

$0.00

ABO-incompatible Kidney Transplantation: Long-Term Outcomes.

ABO-incompatible Kidney Transplantation: Long-Term Outcomes. Tanabe K, Ishida H, Inui M, Okumi ..

$0.00

Anti-HLA-E Monoclonal Antibodies Reacting with HLA-1a and 1b Alleles Like IVIg as Potential IVIg-Immunomimetics: An Evolving Therapeutic Concept.

Anti-HLA-E Monoclonal Antibodies Reacting with HLA-1a and 1b Alleles Like IVIg as Potential IVIg-Imm..

$0.00

Antibodies Against "Danger" in the Dynamic of Post-transplant Circulation.

Antibodies Against "Danger" in the Dynamic of Post-transplant Circulation. Taniguchi M.Clinical..

$0.00

Can We Use Dilution-titration Studies to Identify Clinically Relevant HLA Antibody Specificities?

Can We Use Dilution-titration Studies to Identify Clinically Relevant HLA Antibody Specificities?&nb..

$0.00

Causes of Graft Failure in Simultaneous Pancreas-Kidney Transplantation by Various Time Periods.

Causes of Graft Failure in Simultaneous Pancreas-Kidney Transplantation by Various Time Periods.&nbs..

$0.00

Cells Versus Antibodies in Allograft Destruction - A Historical Perspective.

Cells Versus Antibodies in Allograft Destruction - A Historical Perspective. Brent L.Clinical T..

$0.00

Clinical Relevance of Pre- and Post-Transplant HLA Antibodies, Donor-specific, and Nondonor-specific HLA Antibodies Detected by ELISA in Renal Transplantation.

Clinical Relevance of Pre- and Post-Transplant HLA Antibodies, Donor-specific, and Nondonor-specific..

$0.00

Clinical Strategy for Induction of Transplantation Tolerance Through Mixed Chimerism.

Clinical Strategy for Induction of Transplantation Tolerance Through Mixed Chimerism. Cosimi AB..

$0.00

Desensitization in the Era of Kidney Paired Donation: The Mayo Foundation 3-site Experience.

Desensitization in the Era of Kidney Paired Donation: The Mayo Foundation 3-site Experience. Sc..

$0.00

Donor Risk Factors in Orthotopic Liver Transplant: Analysis of the OPTN/UNOS Registry.

Donor Risk Factors in Orthotopic Liver Transplant: Analysis of the OPTN/UNOS Registry. Kawakita..

$0.00

Donor Specific Antibodies Before and After Kidney Transplant: The University of Colorado Experience.

Donor Specific Antibodies Before and After Kidney Transplant: The University of Colorado Experience...

$0.00

Evolution of Studies of HLA Class I Antigen Processing Machinery (APM) Components in Malignant Cells.

Evolution of Studies of HLA Class I Antigen Processing Machinery (APM) Components in Malignant Cells..

$0.00

Evolving Concepts in Desensitization.

Evolving Concepts in Desensitization. Jordan SC, Vo AA.Clinical Transplants 2013, Chapter 34Abs..

$0.00

Excellent Outcomes with Expanded Criteria Donor Kidneys: The Role of the Recipient's Age.

Excellent Outcomes with Expanded Criteria Donor Kidneys: The Role of the Recipient's Age. Serur..

$0.00

Exchange Donor Renal Transplantation.

Exchange Donor Renal Transplantation. Kim SJ, Kim MS, Park K.Clinical Transplants 2013, Chapter..

$0.00

Fifteen Years Later: Main Lessons from Composite Tissue Allografts.

Fifteen Years Later: Main Lessons from Composite Tissue Allografts. Dubernard JM, Sirigu A, Seu..

$0.00

Fifty Years Later.

Fifty Years Later. Mangan TL, Benedetti KA, Starzl TE.Clinical Transplants 2013, Chapter 11Abst..

$0.00

Gene and Stem Cell Therapy for Diabetes.

Gene and Stem Cell Therapy for Diabetes. Calne RY, Ghoneim MA, Lee KO, Uin GS.Clinical Transpla..

$0.00

Heart Transplantation in an Aging Society: An Analysis of 25 Years of the OPTN/UNOS Registry.

Heart Transplantation in an Aging Society: An Analysis of 25 Years of the OPTN/UNOS Registry. H..

$0.00

HLA Identical Non-Chimeric and HLA Disparate Chimeric Renal Transplant Tolerance.

HLA Identical Non-Chimeric and HLA Disparate Chimeric Renal Transplant Tolerance. Leventhal JR,..

$0.00

HLA in Anthropology: The Enigma of Easter Island.

HLA in Anthropology: The Enigma of Easter Island. Sanchez-Mazas A, Thorsby E.Clinical Transplan..

$0.00

HLA Matching and Kidney Transplantation: Beyond Graft Survival.

HLA Matching and Kidney Transplantation: Beyond Graft Survival. Opelz G, Döhler B.Clinical Tran..

$0.00

HLA Matching at the Epitope Level: The Way to Go.

HLA Matching at the Epitope Level: The Way to Go. Duquesnoy RJ.Clinical Transplants 2013, Chapt..

$0.00

HLA-specific Antibody Distribution in Renal Transplant Waiting List Patients: Utility of Antigen Frequency Data in the Definition of HLA-reactive Epitopes.

HLA-specific Antibody Distribution in Renal Transplant Waiting List Patients: Utility of Antigen Fre..

$0.00

Immunoglobulin G Subclass Analysis of HLA Donor Specific Antibodies in Heart and Renal Transplant Recipients.

Immunoglobulin G Subclass Analysis of HLA Donor Specific Antibodies in Heart and Renal Transplant Re..

$0.00

Immunoregulation and Allogenicity in Cardiac Stem Cell Regenerative Therapy.

Immunoregulation and Allogenicity in Cardiac Stem Cell Regenerative Therapy. Charron D, Al-Dacc..

$0.00

Impact of Solid Phase Antibody Testing on Organ Allocation in the United States.

Impact of Solid Phase Antibody Testing on Organ Allocation in the United States. Reinsmoen NL.C..

$0.00

Incidence and Hazards of Alloantibodies in Renal Transplantation.

Incidence and Hazards of Alloantibodies in Renal Transplantation. Everly MJ.Clinical Transplant..

$0.00

Kidney Failure Requiring Kidney Transplantation After Pancreas Transplant Alone.

Kidney Failure Requiring Kidney Transplantation After Pancreas Transplant Alone. Nata N, Huang ..

$0.00

Living Donor Kidney Transplantation: "Beauty and the Beast"!

Living Donor Kidney Transplantation: "Beauty and the Beast"! Danovitch GM.Clinical Transplants ..

$0.00

Novel Biomarker Combination Predicts Long-term Allograft Outcome.

Novel Biomarker Combination Predicts Long-term Allograft Outcome. Cail J, Huang W, Terasaki PI,..

$0.00

Novel Strategies for Immunological Monitoring of Kidney Transplant Recipients: From Microrna to Alloantibodies.

Novel Strategies for Immunological Monitoring of Kidney Transplant Recipients: From Microrna to Allo..

$0.00

Plasma Cell Biology: Principles for Therapeutic Design.

Plasma Cell Biology: Principles for Therapeutic Design. Woodle ES, Alloway RR, Ejaz NS.Clinical..

$0.00

Post-Transplant Development of C1q-positive HLA Antibodies and Kidney Graft Survival.

Post-Transplant Development of C1q-positive HLA Antibodies and Kidney Graft Survival. Piazza A,..

$0.00

Pre-Nephrectomy Angiotensin II Type 1 Receptor Antibodies in Living Kidney Donors: A Concern?

Pre-Nephrectomy Angiotensin II Type 1 Receptor Antibodies in Living Kidney Donors: A Concern? H..

$0.00

Pre-Transplant Angiotensin II Type 1 Receptor Antibodies: A Risk Factor for Decreased Kidney Graft Function in the Early Post-transplant Period?

Pre-Transplant Angiotensin II Type 1 Receptor Antibodies: A Risk Factor for Decreased Kidney Graft F..

$0.00

Progress and Outcomes of the First High-volume Pediatric Liver Transplantation Program in Saudi Arabia.

Progress and Outcomes of the First High-volume Pediatric Liver Transplantation Program in Saudi Arab..

$0.00

Reduction of HLA Class I Expression by Ribonucleic Acid Interference Mitigates Allogenicity of Human Primary and Immortalized Cells.

Reduction of HLA Class I Expression by Ribonucleic Acid Interference Mitigates Allogenicity of Human..

$0.00

Reflections on the Unique Tolerogenicity of Bone Marrow, the Enigma of Chimerism and Clinical Tolerance.

Reflections on the Unique Tolerogenicity of Bone Marrow, the Enigma of Chimerism and Clinical Tolera..

$0.00

Report from the Japan Registry of Pancreas Transplantation (2000-2012): Outcomes of Pancreas Transplantation from Marginal Donors.

Report from the Japan Registry of Pancreas Transplantation (2000-2012): Outcomes of Pancreas Transpl..

$0.00

Role of Alloimmunity and Autoimmunity in Allograft Rejection.

Role of Alloimmunity and Autoimmunity in Allograft Rejection. Banan B, Xu Z, Gunasekaran M, Moh..

$0.00

Statins in Heart Transplantation.

Statins in Heart Transplantation. Kittleson MM, Kobashigawa JA.Clinical Transplants 2013, Chapt..

$0.00

The Big Picture: A Case Report of Antibody Mediated Rejection and Treatment After Lung Transplantation Illustrating the Need to Correlate Laboratory Findings with Clinical Status.

The Big Picture: A Case Report of Antibody Mediated Rejection and Treatment After Lung Transplantati..

$0.00

The Differential Pathogenicity of HLA Antibodies: What a Large Cross-sectional Study Can Tell Us.

The Differential Pathogenicity of HLA Antibodies: What a Large Cross-sectional Study Can Tell Us.&nb..

$0.00

The Non-classical Antigens of HLA-G and HLA-E as Diagnostic and Prognostic Biomarkers and as Therapeutic Targets in Transplantation and Tumors.

The Non-classical Antigens of HLA-G and HLA-E as Diagnostic and Prognostic Biomarkers and as Therape..

$0.00